Keeping Track: Enhertu, Nubeqa Grow With RTOR; Interchangeable Cimerli And Another Nuplazid CRL

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

The FDA topped off last week with two approvals under its popular Real-Time Oncology Review (RTOR) program, granting new indications to AstraZeneca PLC/Daiichi Sankyo Co., Ltd.’s Enhertu in HER2-low breast cancer and Bayer AG/Orion Corporation’s Nubeqa in hormone-sensitive prostate cancer.

While both approvals came in advance of the user fee goal date, the two-month review of the new Enhertu indication...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America